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A new look at a familiar question
What is the optimal technique for pancreatic anastomosis following pancreaticoduodenectomy (PD)? While this question
is not new, it remains important since clinically-relevant post operative pancreatic fistulae (PF) still drive most
PD-associated morbidity and mortality. For the contest of pancreaticojejunostomy (PJ) versus pancreaticogastrostomy
(PG),we have plenty of analyses to consider. These range from observational studies through to randomized controlled trials
(RCTs).We have five available systematic reviews and meta-analyses which collectively fail to identify a significant benefit in
terms of PF for either technique. Why then is HPB publishing yet another meta-analysis on this question? For me, the
reasons emerged upon careful review of the study by Hallet, et al. of Toronto. Four RCTs with 676 patients were analyzed
after meeting explicit eligibility criteria. Two of these were only recently reported (Topol 2013, Figueras 2013) and absent
from prior meta-analyses. One older but important RCT (Yeo 1995) was excluded, presumably as it could not meet the
criteria of using the ISGPF fistula definition established in 2005.Opinions about that may vary.Nevertheless,Hallet et al. can
be proud of the rigor and purpose of their analysis. They expose and educate as to the weaknesses of prior meta-analyses,
and use sound methodology for a best new look at this familiar question.We learn of the CONSORT statement, the GRADE
system to evaluate overall evidence strength, and the Fragility Index for a given RCT. In terms of the primary outcome of PF,
pancreaticogastrostomy (PG) took the prize, but only by a small margin and upon evidence of moderate strength. PG and
PJ were equivalent for several secondary outcomes as you’ll see. As I noted last month in HPB, pancreatic surgeons should
use their preferred best technique to achieve the best outcomes for their patients.
Mark Callery
R1 margin in colorectal liver metastases (CRLM): a technical failure or
marker of disease biology?
Obtaining an R0 margin has been considered a cornerstone principle of cancer surgery since Halstead’s pioneering work on
radical mastectomy. Transitioning to a less aggressive surgical approaches as adjuvant therapies improved required “thought
leaders” to change surgical dogma. A recent personal observation at international HPB conferences has been the move away
from the concept of neoadjuvant chemotherapy for CRLM by modern day HPB “thought leaders”. In this issue of HPB,
Truant et al. add to the debate of the role of neoadjuvant therapy in those with adverse prognostic factors.
They provide a large data series with a detailed statistical analysis of patients undergoing liver resection for CRLM with
perioperative chemotherapy. Of the 273 patients studied, 59 (22%) were reported as having an R1 (<1 mm) margin.
Although margin status appeared a significant prognostic factor on univariate analysis, it did not remain significant once
patients were matched by propensity scoring or analysed by multivariate analysis. In studying the data, it is clear that those
patients who had R1margins had more advanced or biologically aggressive tumours. In addition surgical margin recurrence
was rarely a determining factor in outcome. A total of 184 (67%) developed recurrence with only 22 (8%) patients
developing margin recurrence. Thus the development of distant disease was what determined long term survival. The
authors provide a number of possibilities for the lack of effect of R0 margin but strongly advocate from their data that
perioperative chemotherapy should be considered as standard practice for patients with CRLM.
So what should a surgeon take from this paper? Firstly we must still strive for R0 margin. Chemotherapy cannot
overcome poor surgery especially in those patients with favourable disease. The accurate assessment of margin status
remains problematic due to hepatic parenchymal transection techniques. In those patients with adverse prognostic factors
associated with CRLM the role of perioperative chemotherapy would appear to remain an important co-contributor to
improving outcomes.
Saxon Connor
Making sense of the liver volume/function relationship in health and
disease will lead to safer liver surgery
CT scan based liver volume analysis has become a standard technique for complex or extended liver resections as a means
of estimating likelihood of liver failure and improving patient safety. Volume analysis of the predicted future liver remnant
is known to work well for patients with normal or near normal liver function with predicted minimum liver volumes of
around 25%, reliably avoiding post-operative liver failure. Where volume analysis falls down is in patients with abnormal
liver function and particularly cirrhosis. The problem is essentially that the liver function can be highly variable at the
dysfunctional end of the scale and the volume function relationship becomes unpredictable.
Kim and colleagues from South Korea have presented an analysis combining conventional hepatic volumetry with
retention of indocyanine green (ICG) at 15 minutes. In this study, they have confirmed that in healthy liver, volume
measurement alone can reliably identify patients at risk of developing post operative liver failure. In patients with under-
lying liver disease or cirrhosis, expressing the future liver remnant volume in relation to the ICG15 retention time also
provided a clear cut off value that identified a safe level at which resection could proceed. This ratio of future liver
remnant volume to ICG15 was >1.9. This therefore provides a useful and practical approach to estimate patient safety in
patients undergoing major resection. Patients with healthy liver probably only need to undergo volume analysis and if the
future liver remnant is greater than 25%, resection can proceed. Those with cirrhosis or marked fibrosis should undergo
both volume analysis and measurement of ICG retention at 15 minutes. If the ratio of these measurements (FLR : ICG15)
is >1.9, resection can proceed safely but if less than this then a modified approach should be used or there will be a
significant risk of liver failure.
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